Published : 12 Dec 2023
Happy with the delivery of the first Assignment, our US based client has now appointed Aagami for Acquisition/Partnering for their Patented small molecule NSAID combination for Migraine using 505(b)(2) pathway.
Drugs available currently relieve some symptoms, but all have potential side effects or tolerability issues. Our client’s drug asset is a new, safer, and better medication to help prevent and treat migraine headaches.
The objective of the client’s invention is to provide treatment of migraine and other indications such as pain, fever, dysmenorrhea, acute migraine, menstrual or pre-menstrual migraine.
This oral tablet drug asset combines an anti-inflammatory & analgesic drug (COX-2 inhibitor) with low-dose active aspirin derivative.
· Prevents the onset of a migraine and reduce the intensity of migraine.
· Protects the patient from the neurological and physical symptoms that are usually associated with migraine.
Asset Features & Benefits
· IP Protected (2 patents).
· Provides anti-inflammatory and analgesic effects of a COX-2 inhibitor and contains low-dose aspirin. Cox-2 regulation is important in the pathogenesis and treatment of migraine.
· Cox-2 inhibitors and low dose aspirin are both useful in prevention of migraine (inclusive of menstrual migraine).
· Provides cardiovascular benefit of low-dose aspirin. Addresses cardiovascular risk of all Cox-2 selective NSAIDs.
· Increases patient adherence and safety.
· Can be combined with existing non-NSAID therapies.
· Recent FDA approval of Elyxyb and Vazalore increases the probability of medium-term price stability of this drug asset, as well as the likelihood of FDA approval.
This is the only product that offers all the features and advantages that currently no other provides in the market.
The first company to bring this product to market will greatly profit from its effectiveness and cutting edge design that truly occupies a unique NSAID class by itself. This drug asset could be introduced in the market quickly as it uses 505(b)2 pathway.
Our client is a technology developer and not a commercial company. Hence client is offering acquisition/Partnering/Licensing of its Intellectual Property(IP).
More details are available on request. Our Client is also available for an exploratory meeting.
If you would like to know more about this opportunity, please contact us.